Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04182659|
Recruitment Status : Recruiting
First Posted : December 2, 2019
Last Update Posted : December 4, 2019
|Condition or disease||Intervention/treatment||Phase|
|Gulf War Syndrome Gulf War Illness Headache Muscle Pain Joint Pain||Device: Transcranial Magnetic Stimulation Device: Sham Transcranial Magnetic Stimulation||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||There are two groups: one will receive active rTMS and the other group will receive sham rTMS.|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Masking Description:||This is a double-blinded study where only the statistician is aware of the randomization.|
|Official Title:||Long Term Efficacy of Neuronavigation Guided rTMS in Alleviating Gulf War Illness Related Headaches and Pain Symptoms|
|Actual Study Start Date :||October 1, 2019|
|Estimated Primary Completion Date :||September 30, 2022|
|Estimated Study Completion Date :||September 30, 2022|
Active Comparator: Active rTMS at the LMC
Subjects will receive the repetitive Transcranial Magnetic Stimulation (rTMS) study procedure at the left motor cortex (LMC)
Device: Transcranial Magnetic Stimulation
A non-invasive treatment that emits magnetic pulses to stimulate the brain.
Sham Comparator: Sham rTMS at the LMC
Sham rTMS will appear the same as the active, with the same parameters, but will not receive the actual magnetic stimulation to the LMC.
Device: Sham Transcranial Magnetic Stimulation
Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
- Change from baseline to post treatment of GWI-related pain and headaches [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]This outcome will be measured through daily self-reporting logs that tracks headache, muscle, and joint pain. A numerical rating scale of 0, being no pain, to 10, being worst possible pain, will be used to report pain and headaches.
- Change from baseline to post treatment of sensory and affective aspects of pain [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]Short Form McGill Pain Questionnaire (SF-MPQ): This is a self-report questionnaire that allows individuals to describe the quality and intensity of pain they are experiencing. This will be used to assess the sensory and affective aspects of muscle and joint pain.
- Change from baseline to post treatment of headaches [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]The Headache Impact Test (HIT-6) will be used to measure how headaches affect the individual's ability to function in different domains. This 6-question form assesses the severity of headache pain and is scored with a range of 36-78, with higher scores indicating a larger impact of headaches on functionality.
- Change from baseline to post treatment of quality of life [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]The Short Form Health Survey-36 (SF-36) is a self-reported survey of patient health. It is a measure of health status and quality of life in regards to eight main areas: vitality, physical functioning, bodily pain, health perceptions, physical, emotional, and social role functioning and mental health.
- Change from baseline to post treatment of body pain [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]A Brief Pain Inventory-Short Form (BPI-SF) questionnaire will also be used to assess the severity of pain and the impact of pain on daily functions. The BPI-SF consists of five questions. Four items measure pain on 11-point response scales from 0 to 10 ("No Pain" to "Pain as bad as you can imagine". Another item, containing 7 sub-questions, evaluates the level of pain interference with daily functioning on 11-point response scales from 0 to 10 ("Does not interfere" to "Completely interferes").
- Change from baseline to post treatment of muscle pain [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]The New Clinical Fibromyalgia Diagnostic Criteria - Part 1 will be used to assess muscle pain. Patients will be asked to rate the average (over the past 24 hours) intensity of muscle pain for up to 12 locations of the body.
- Change from baseline to post treatment of fibromyalgia [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]A Revised Fibromyalgia Impact Questionnaire will be used to evaluate the function, overall impact and symptoms of Fibromyalgia. There are a total of 21 questions, each with a range of 0-10, with 10 being either "very difficult" or "always."
- Change from baseline to post treatment of neurobehavioral symptoms [ Time Frame: The Neurobehavioral Symptoms Inventory (NSI) is a self-report questionnaire on the severity of various behavioral symptoms and is measured using a 5-item scale. It asks the subjects to indicate the extent to which each symptom has disturbed them. ]Baseline, 1-week, 1-month, 2-month, and 3-month
- Change from baseline to post treatment of sleep quality [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]The Pittsburgh Sleep Quality Index (PSQI) questionnaire has nineteen individual items which are used to generate seven composite scores on: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Questions are either free-response or have a range from 0-3, with 3 being "more frequent" or "very bad."
- Change from baseline to post treatment of sleep difficulties [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]The Insomnia Severity Index measures the severity of an individual's sleep difficulties. All questions range from 0-4 and the sum of the answers would give the total score. The total score range from 0-28.
- Change from baseline to post treatment of fatigue [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]The Flinders Fatigue Scale measures daytime fatigue associated with insomnia through a 7-item questionnaire. The questions range from 1-5, with 5 being "extremely" or "entirely."
- Change from baseline to post treatment of PTSD symptoms [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]The Clinician-Administered PTSD Scale (CAPS-5), 30-item structured interview that can be used to diagnose PTSD and associated symptoms, will be used to assess PTSD symptoms
- Change in opioid-based pain medication usage [ Time Frame: Baseline, 1-week, 1-month, 2-month, and 3-month ]Medication assessment consists of daily chronic and breakthrough opioid usage for pain or headache. Average daily dosage will be converted to equal-potent oral Morphine Sulfate dosage based on the clinical opioid conversion table used by the VA San Diego Healthcare System Pain Service and University of California, San Diego, Center for Pain Medicine. The study participants will be asked to remain on the same analgesic medication(s) during the study period but are allowed to titrate down their narcotic usage.
- Explore changes in supraspinal resting state functional connectivity [ Time Frame: Baseline and 1-week post treatment ]The outcome measure will be assessed through functional magnetic imaging scans and subsequent processing.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04182659
|Contact: Alphonsa Kunnel, BSfirstname.lastname@example.org|
|United States, California|
|VA Palo Alto||Recruiting|
|Palo Alto, California, United States, 94304|
|Contact: Angela Phillips, PhD 650-493-5000 ext 62179 email@example.com|
|Principal Investigator: Maheen Adamson, PhD|
|VA San Diego Healthcare System||Recruiting|
|San Diego, California, United States, 92161|
|Contact: Alphonsa Kunnel, BS 858-210-8908 firstname.lastname@example.org|
|Principal Investigator: Albert Y Leung, MD|
|United States, Georgia|
|Decatur, Georgia, United States, 30033|
|Contact: Gabriell Champion, BS 404-321-6111 ext 20627 Gabriell.Champion@va.gov|
|Principal Investigator: Keith McGregor, PhD|
|Principal Investigator:||Albert Leung, M.D.||San Diego Veterans Healthcare System|